May 2020
Vol 7 | Issue 305

Q&A with David Jorden – Nanospectra Biosciences


Principal Series:

Nanospectra Biosciences is a medical device company pioneering the patient-centric use of nanomedicine for selective thermal ablation. The Company’s technology allows for the selective thermal ablation of solid tumors due to the preferential and passive accumulation of proprietary gold nanoshells in the leaky vasculature of neoplastic tissue. Targeted thermal ablation occurs when low power laser energy is brought into immediate proximity of the tumor tissue and is transduced via the optical properties of the gold nanoshells into heat sufficient to kill the cancer cells. The laser energy is sub-ablative in the absence of the nanoshells thus sparing healthy tissue. The inert nanoshells consist of a gold metal shell and a non-conducting silica core and serve as the exogenous absorber of the near infrared laser energy delivered by an optical fiber diffuser.


Family Office Insights is a voluntary, “opt-in” collaborative peer-to-peer community of single family offices, qualified investors and institutional investors. Join the community here

What is the market opportunity in the lead prostate indication?

In the lead prostate cancer indication, the approach to focal therapy must be cognizant of both efficacy and side effects. Prostate cancer is a slow progression disease where the adverse treatment effects of erectile dysfunction and incontinence can be significant drawbacks to patient quality of life. Consequently, the opportunity to ablate a tumor/lesion on a basis conformal to the tumor's shape while sparing healthy tissue (such as vascular nerve bundles and urinary sphincter) offers a significant patient benefit.
Nanospectra’s unique ultra-focal therapy for ablation of prostate tissue will occupy an attractive and important middle-ground between “active surveillance” and the established radical treatment approaches (radical prostatectomy, radiation). Paired with effective targeted fusion biopsy and the ability to properly image and visualize a lesion/region of interest, targeted treatment of the localized disease becomes an attractive option for patients seeking disease treatment and side effects avoidance.
In prostate, approximately 80% of the ~175,000 annual (US only) new prostate cancer diagnoses represent localized disease. Estimates are that up to 40-50% of radical prostate treatments (surgery/radiation) could be viable candidates for effective focal therapy. 5,000 AuroLase treatments are estimated to generate $30 million of annual revenues with only 50-60 practicing clinicians. $60-$100 million of annual revenues (US only) can be reasonably modeled based on the addressable market opportunity.

What are the company's current milestones?

The capital raised here will complete the pivotal clinical study in prostate and allow the company to submit its de novo 510(k) device application by an estimated late 2nd quarter 2021 timepoint. The full dataset for prostate tissue ablation will meet the FDA's published requirement for treatment of at least 100 subjects. In addition, initial clinical data in the intended second organ site should be available over the next 6-9 months in low risk papillary thyroid carcinoma (PTC). PTC shares many similarities to prostate cancer as it is prone to over-treatment with resulting negative impact on patient quality of life.

Briefly describe the company's business model.

The revenue model consists of the sale of consumable proprietary gold nanoshells and a disposable laser delivery device. Customer/facility capital investment is modest and consists of a low power laser device if necessary. Therefore, the cost of entry for a site/practice that wishes to directly understand efficacy and how the technology fits within treatment modalities and practice patterns is almost all variable. This is in comparison to material capital investment required in competing focal therapy approaches - e.g., $500,000 - $1,000,000 to enable high intensity focused ultrasound. AuroShells are manufactured directly by Nanospectra as a core competency at reasonable scale and cost and the disposable laser catheter was also developed by the company and is manufactured by a CMO.

David Jorden – Nanospectra Biosciences

I have now been involved directly in life science businesses for almost 20 years while my original career was on the investment buy-side as an analyst/portfolio manager. Post graduate school at Northwestern’s Kellogg School, I spent about 10-11 years with an institutional Houston based money manager named Fayez Sarofim & Co. I was myself a passive investor in Nanospectra beginning in about 2005/2006 and therefore familiar with the company and the technology. I joined Nanospectra as CEO in late spring 2013 in conjunction with a recapitalization of the company which I helped structure.  Contact David: